Cachexia in patients with oesophageal cancer

Nature Reviews Clinical Oncology

Volumn 13, Issue 3, 2016, Pages 185-198

  Anandavadivelan, Poorna ^a   Lagergren, Pernilla ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APPETITE STIMULANT; C REACTIVE PROTEIN; CORTICOSTEROID; GHRELIN; OMEGA 3 FATTY ACID; THALIDOMIDE;

BODY COMPOSITION; BODY FAT; CACHEXIA; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; DISEASE SEVERITY; DYSPHAGIA; ESOPHAGUS CANCER; FEEDING DIFFICULTY; HUMAN; INFLAMMATION; LOSS OF APPETITE; MALNUTRITION; MUSCLE MASS; NONHUMAN; PATIENT ASSESSMENT; PHYSICAL ACTIVITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SARCOPENIC OBESITY; WEIGHT REDUCTION; COMPLICATION; ESOPHAGEAL NEOPLASMS; MORTALITY; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BODY COMPOSITION; CACHEXIA; ESOPHAGEAL NEOPLASMS; HUMANS; NUTRITION ASSESSMENT; NUTRITIONAL STATUS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84959160875     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.200     Document Type: Review

References (134)

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015).
2. Arnold, M., Soerjomataram, I., Ferlay, J. & Forman, D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64, 381-387 (2014).
3. Sjoquist, K. M. et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12, 681-692 (2011).
4. Makowiec, F. et al. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. J. Gastrointest. Surg. 17, 1193-1201 (2013).
5. Adenis, A. et al. Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer 13, 413 (2013).
6. Bozzetti, F. Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 17, 279-284 (2009).
7. Tuca, A., Jimenez-Fonseca, P. & Gascon, P. Clinical evaluation and optimal management of cancer cachexia. Crit. Rev. Oncol. Hematol. 88, 625-636 (2013).
8. Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489-495 (2011).
9. Johns, N., Stephens, N. A. & Fearon, K. C. Muscle wasting in cancer. Int. J. Biochem. Cell Biol. 45, 2215-2229 (2013).
10. Blum, D. et al. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model - a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25, 1635-1642 (2014).
11. Fearon, K. C., Voss, A. C. & Hustead, D. S. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr. 83, 1345-1350 (2006).
12. Fearon, K., Arends, J. & Baracos, V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10, 90-99 (2013).
13. Hoyo, C. et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int. J. Epidemiol. 41, 1706-1718 (2012).
14. Cooper, J. S. et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281, 1623-1627 (1999).
15. Lagarde, S. M., Vrouenraets, B. C., Stassen, L. P. & van Lanschot, J. J. Evidence-based surgical treatment of esophageal cancer: overview of highquality studies. Ann. Thorac. Surg. 89, 1319-1326 (2010).
16. Martin, L. & Lagergren, P. Risk factors for weight loss among patients surviving 5 years after esophageal cancer surgery. Ann. Surg. Oncol. 22, 610-616 (2015).
17. Martin, L. & Lagergren, P. Long-term weight change after oesophageal cancer surgery. Br. J. Surg. 96, 1308-1314 (2009).
18. Scarpa, M. et al. Systematic review of health-related quality of life after esophagectomy for esophageal cancer. World J. Gastroenterol. 17, 4660-4674 (2011).
19. Jeejeebhoy, K. N. Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia: overlap of clinical features. Curr. Opin. Clin. Nutr. Metab. Care 15, 213-219 (2012).
20. Muscaritoli, M. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexiaanorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin. Nutr. 29, 154-159 (2010).
21. Jacquelin-Ravel, N. & Pichard, C. Clinical nutrition, body composition and oncology: a critical literature review of the synergies. Crit. Rev. Oncol. Hematol. 84, 37-46 (2012).
22. Thibault, R., Genton, L. & Pichard, C. Body composition: why, when and for who? Clin. Nutr. 31, 435-447 (2012).
23. Martin, L. et al. Diagnostic criteria for the classification of cancer-associated weight loss. J. Clin. Oncol. 33, 90-99 (2015).
24. Cruz-Jentoft, A. J. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on sarcopenia in older people. Age Ageing 39, 412-423 (2010).
25. Fearon, K., Evans, W. J. & Anker, S. D. Myopenia - a new universal term for muscle wasting. J. Cachexia Sarcopenia Muscle 2, 1-3 (2011).
26. Martin, L. et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31, 1539-1547 (2013).
27. Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9, 629-635 (2008).
28. Laviano, A., Meguid, M. M., Inui, A., Muscaritoli, M. & Rossi-Fanelli, F. Therapy insight: cancer anorexiacachexia syndrome-when all you can eat is yourself. Nat. Clin. Pract. Oncol. 2, 158-165 (2005).
29. Daly, J. M. et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J. Am. Coll. Surg. 190, 562-572 (2000).
30. Ryan, A. M. et al. Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit. Clin. Nutr. 25, 386-393 (2006).
31. van der Schaaf, M. K. et al. The influence of preoperative weight loss on the postoperative course after esophageal cancer resection. J. Thorac. Cardiovasc. Surg. 147, 490-495 (2014).
32. Tisdale, M. J. Mechanisms of cancer cachexia. Physiol. Rev. 89, 381-410 (2009).
33. Donohoe, C. L., Ryan, A. M. & Reynolds, J. V. Cancer cachexia: mechanisms and clinical implications. Gastroenterol. Res. Pract. 2011, 601434 (2011).
34. Baracos, V. E. Cancer-associated cachexia and underlying biological mechanisms. Annu. Rev. Nutr. 26, 435-461 (2006).
35. Suzuki, H. et al. Cancer cachexia pathophysiology and translational aspect of herbal medicine. Jpn J. Clin. Oncol. 43, 695-705 (2013).
36. McMillan, D. C. Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 12, 223-226 (2009).
37. Deans, D. A. et al. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br. J. Cancer 100, 63-69 (2009).
38. da Silva, J. B., Mauricio, S. F., Bering, T. & Correia, M. I. The relationship between nutritional status and the Glasgow prognostic score in patients with cancer of the esophagus and stomach. Nutr. Cancer 65, 25-33 (2013).
39. Vashist, Y. K. et al. Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann. Surg. Oncol. 18, 1130-1138 (2011).
40. Nozoe, T., Saeki, H. & Sugimachi, K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am. J. Surg. 182, 197-201 (2001).
41. Shimada, H. et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J. Surg. Oncol. 83, 248-252 (2003).
42. Tsai, V. W. et al. Anorexia/cachexia of chronic diseases: a role for the TGFβ family cytokine MIC-1/GDF15. J. Cachexia Sarcopenia Muscle 3, 239-243 (2012).
43. Gelin, J. et al. Role of endogenous tumor necrosis factor α and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 51, 415-421 (1991).
44. Skipworth, R. J., Stewart, G. D., Dejong, C. H., Preston, T. & Fearon, K. C. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin. Nutr. 26, 667-676 (2007).
45. Whitehouse, A. S. & Tisdale, M. J. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br. J. Cancer 89, 1116-1122 (2003).
46. Watchorn, T. M., Waddell, I., Dowidar, N. & Ross, J. A. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J. 15, 562-564 (2001).
47. Deans, D. A. et al. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br. J. Cancer 95, 1568-1575 (2006).
48. Groblewska, M., Mroczko, B., Sosnowska, D. & Szmitkowski, M. Interleukin 6 and C-reactive protein in esophageal cancer. Clin. Chim. Acta 413, 1583-1590 (2012).
49. Makuuchi, Y. et al. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci. 104, 1045-1051 (2013).
50. Skipworth, R. J. et al. Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. Br. J. Cancer 102, 665-672 (2010).
51. Deans, C. et al. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer 103, 1810-1818 (2005).
52. Bing, C. et al. Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinomaderived lipid-mobilizing factor. Br. J. Cancer 86, 612-618 (2002).
53. Islam-Ali, B., Khan, S., Price, S. A. & Tisdale, M. J. Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br. J. Cancer 85, 758-763 (2001).
54. Arner, P. Medicine. Lipases in cachexia. Science 333, 163-164 (2011).
55. Fouladiun, M. et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care - correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 103, 2189-2198 (2005).
56. Cheng, Y. et al. Prognostic value of body mass index for patients undergoing esophagectomy for esophageal squamous cell carcinoma. Jpn J. Clin. Oncol. 43, 146-153 (2013).
57. Bhayani, N. H. et al. Does morbid obesity worsen outcomes after esophagectomy? Ann. Thorac. Surg. 95, 1756-1761 (2013).
58. Zhang, S. S. et al. The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br. J. Cancer 109, 2894-2903 (2013).
59. Batista, M. L. Jr et al. Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. Cytokine 61, 532-539 (2013).
60. Deans, D. A. et al. Expression of the proteolysis-inducing factor core peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastrooesophageal malignancy. Br. J. Cancer 94, 731-736 (2006).
61. Penna, F. et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. 182, 1367-1378 (2013).
62. Tardif, N., Klaude, M., Lundell, L., Thorell, A. & Rooyackers, O. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am. J. Clin. Nutr. 98, 1485-1492 (2013).
63. Wu, J., Huang, C., Xiao, H., Tang, Q. & Cai, W. Weight loss and resting energy expenditure in male patients with newly diagnosed esophageal cancer. Nutrition 29, 1310-1314 (2013).
64. Cao, D. X. et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin. Nutr. 29, 72-77 (2010).
65. Davis, M. P., Dreicer, R., Walsh, D., Lagman, R. & LeGrand, S. B. Appetite and cancer-associated anorexia: a review. J. Clin. Oncol. 22, 1510-1517 (2004).
66. Inui, A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 59, 4493-4501 (1999).
67. Sarraf, P. et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J. Exp. Med. 185, 171-175 (1997).
68. Grunfeld, C. et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J. Clin. Invest. 97, 2152-2157 (1996).
69. Finck, B. N., Kelley, K. W., Dantzer, R. & Johnson, R. W. In vivo and in vitro evidence for the involvement of tumor necrosis factor-alpha in the induction of leptin by lipopolysaccharide. Endocrinology 139, 2278-2283 (1998).
70. Simons, J. P., Schols, A. M., Campfield, L. A., Wouters, E. F. & Saris, W. H. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin. Sci. (Lond.) 93, 273-277 (1997).
71. Wallace, A. M., Sattar, N. & McMillan, D. C. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin. Cancer Res. 4, 2977-2979 (1998).
72. Diakowska, D. et al. Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract. Cytokine 51, 132-137 (2010).
73. Jiang, N. et al. Clinical determinants of weight loss in patients with esophageal carcinoma during radiotherapy: a prospective longitudinal view. Asian Pac. J. Cancer Prev. 15, 1943-1948 (2014).
74. Martin, L., Jia, C., Rouvelas, I. & Lagergren, P. Risk factors for malnutrition after oesophageal and cardia cancer surgery. Br. J. Surg. 95, 1362-1368 (2008).
75. Ribi, K. et al. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer 17, 1109-1116 (2009).
76. Cools-Lartigue, J. et al. Management of dysphagia in esophageal adenocarcinoma patients undergoing neoadjuvant chemotherapy: can invasive tube feeding be avoided? Ann. Surg. Oncol. 22, 1858-1865 (2015).
77. Miller, K. R. & Bozeman, M. C. Nutrition therapy issues in esophageal cancer. Curr. Gastroenterol. Rep. 14, 356-366 (2012).
78. Prado, C. M. et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin. Cancer Res. 13, 3264-3268 (2007).
79. Cosquéric, G. et al. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br. J. Nutr. 96, 895-901 (2006).
80. Lieffers, J. R., Bathe, O. F., Fassbender, K., Winget, M. & Baracos, V. E. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br. J. Cancer 107, 931-936 (2012).
81. Awad, S. et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31, 74-77 (2012).
82. Yip, C. et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur. Radiol. 24, 998-1005 (2014).
83. Ida, S. et al. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy. Ann. Surg. Oncol. 21, 3675-3679 (2014).
84. Jack, S. et al. The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. Eur. J. Surg. Oncol. 40, 1313-1320 (2014).
85. Tan, B. H., Birdsell, L. A., Martin L, Baracos, V. E. & Fearon, K. C. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res. 15, 6973-6979 (2009).
86. Prado, C. M. et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 15, 2920-2926 (2009).
87. Huillard, O. et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br. J. Cancer 108, 1034-1041 (2013).
88. Lagergren, J. & Lagergren, P. Recent developments in esophageal adenocarcinoma. CA Cancer J. Clin. 63, 232-248 (2013).
89. Riccardi, D. & Allen, K. Nutritional management of patients with esophageal and esophagogastric junction cancer. Cancer Control 6, 64-72 (1999).
90. Martin, L., Lagergren, J., Lindblad, M., Rouvelas, I. & Lagergren, P. Malnutrition after oesophageal cancer surgery in Sweden. Br. J. Surg. 94, 1496-1500 (2007).
91. D'Journo, X. B. et al. Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for cancer. Dis. Esophagus 25, 527-534 (2012).
92. Doki, Y. et al. Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery 139, 797-805 (2006).
93. Koizumi, M. et al. Postoperative weight loss does not resolve after esophagectomy despite normal serum ghrelin levels. Ann. Thorac Surg. 91, 1032-1037 (2011).
94. Miyazaki, T. et al. Ghrelin level and body weight loss after esophagectomy for esophageal cancer. J. Surg. Res. 176, 74-78 (2012).
95. Yamamoto, K. et al. Reduced plasma ghrelin levels on day 1 after esophagectomy: a new predictor of prolonged systemic inflammatory response syndrome. Surg. Today 43, 48-54 (2013).
96. Djarv, T., Lagergren, J., Blazeby, J. M. & Lagergren, P. Long-term health-related quality of life following surgery for oesophageal cancer. Br. J. Surg. 95, 1121-1126 (2008).
97. Boyce, H. W. Jr. Palliation of dysphagia of esophageal cancer by endoscopic lumen restoration techniques. Cancer Control 6, 73-83 (1999).
98. Wheelwright, S. et al. A systematic review of health-related quality of life instruments in patients with cancer cachexia. Support Care Cancer 21, 2625-2636 (2013).
99. Blazeby, J. M. et al. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of Life Study Group. Eur. J. Cancer 32A, 1912-1917 (1996).
100. Blazeby, J. M. et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur. J. Cancer 39, 1384-1394 (2003).
101. Johnson, C. et al. EORTC QOL Module for Cancer Cachexia (QLQ-CAX25) EORTC Quality of Life Department [online], http://groups.eortc.be/qol/eortc-qol-module-cancer-cachexia-qlq-cax25 (2015).
102. Prado, C. M., Birdsell, L. A. & Baracos, V. E. The emerging role of computerized tomography in assessing cancer cachexia. Curr. Opin. Support. Palliat. Care 3, 269-275 (2009).
103. de Vos-Geelen, J., Fearon, K. C. & Schols, A. M. The energy balance in cancer cachexia revisited. Curr. Opin. Clin. Nutr. Metab. Care 17, 509-514 (2014).
104. Fearon, K. C. Cancer cachexia and fat-muscle physiology. N. Engl. J. Med. 365, 565-567 (2011).
105. Arends, J. et al. ESPEN Guidelines on enteral nutrition: Non-surgical oncology. Clin. Nutr. 25, 245-259 (2006).
106. Bauer, J. D. et al. Evidence based practice guidelines for the nutritional management of cancer cachexia. Nutrition & Dietetics 63, S3-S32 (2006).
107. Mariette, C., De Botton, M. L. & Piessen, G. Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice? Ann. Surg. Oncol. 19, 2128-2134 (2012).
108. Fietkau, R. et al. A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial. Cancer 119, 3343-3353 (2013).
109. Llop-Talaveron, J. M. et al. Artificial nutritional support in cancer patients after esophagectomy: 11 years of experience. Nutr. Cancer 66, 1038-1046 (2014).
110. Ligthart-Melis, G. C. et al. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer. Dis. Esophagus 26, 587-593 (2013).
111. Starr, B., Davis, S., Ayala-Peacock, D., Blackstock, W. A. & Levine, E. A. Reassessment of the role of enteral tube feedings for patients with esophageal cancer. Am. Surg. 80, 752-758 (2014).
112. Horowitz, M., Neeman, E., Sharon, E. & Ben-Eliyahu, S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat. Rev. Clin. Oncol. 12, 213-226 (2015).
113. Bozzetti, F. et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin. Nutr. 28, 445-454 (2009)
114. Buijs, N. et al. Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-term survival. Am. J. Clin. Nutr. 92, 1151-1156 (2010).
115. Ries, A. et al. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat. Med. 26, 294-304 (2012).
116. Aapro, M. et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann. Oncol. 25, 1492-1499 (2014).
117. Sultan, J. et al. Randomized clinical trial of omega-3 fatty acid-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing oesophagogastric cancer surgery. Br. J. Surg. 99, 346-355 (2012).
118. Peng, J., Cai, J., Niu, Z. X. & Chen, L. Q. Early enteral nutrition compared with parenteral nutrition for esophageal cancer patients after esophagectomy: a meta-analysis. Dis. Esophagus http://dx.doi.org/10.1111/dote.12337.
119. Wright, G. P., Foster, S. M. & Chung, M. H. Esophagectomy in patients with prior percutaneous endoscopic gastrostomy tube placement. Am. J. Surg. 207, 361-365 (2014).
120. Weimann, A. et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin. Nutr. 25, 224-244 (2006).
121. Pascual Lopez, A. et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Symptom Manage. 27, 360-369 (2004).
122. Lesniak, W., Bala, M., Jaeschke, R. & Krzakowski, M. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome - a systematic review and meta-analysis. Pol. Arch. Med. Wewn. 118, 636-644 (2008).
123. Madeddu, C., Maccio, A., Panzone, F., Tanca, F. M. & Mantovani, G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin. Pharmacother. 10, 1359-1366 (2009).
124. Loprinzi, C. L. et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J. Clin. Oncol. 17, 3299-3306 (1999).
125. Yamamoto, K. et al. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery 148, 31-38 (2010).
126. Takata, A. et al. Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy. Ann. Surg. 262, 230-236 (2014).
127. Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543 (2010).
128. Tisdale, M. J. Reversing cachexia. Cell 142, 511-512 (2010).
129. Wilkes, E. A. et al. Poor tolerability of thalidomide in end-stage oesophageal cancer. Eur. J. Cancer Care (Engl.) 20, 593-600 (2011).
130. Khan, Z. H. et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol. Ther. 17, 677-682 (2003).
131. Zinna, E. M. & Yarasheski, K. E. Exercise treatment to counteract protein wasting of chronic diseases. Curr. Opin. Clin. Nutr. Metab. Care 6, 87-93 (2003).
132. Lenk, K., Schuler, G. & Adams, V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle 1, 9-21 (2010).
133. Oldervoll, L. M. et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 16, 1649-1657 (2011).
134. Lonbro, S. The effect of progressive resistance training on lean body mass in post-treatment cancer patients - a systematic review. Radiother. Oncol. 110, 71-80 (2014).